These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 16887103

  • 1. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
    Lengler J, Omann M, Düvier D, Holzmüller H, Gregor W, Salmons B, Günzburg WH, Renner M.
    Biochem Pharmacol; 2006 Sep 28; 72(7):893-901. PubMed ID: 16887103
    [Abstract] [Full Text] [Related]

  • 2. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L, Waxman DJ, Chen D, Kufe DW.
    Cancer Res; 1996 Mar 15; 56(6):1331-40. PubMed ID: 8640822
    [Abstract] [Full Text] [Related]

  • 3. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
    Chen L, Yu LJ, Waxman DJ.
    Cancer Res; 1997 Nov 01; 57(21):4830-7. PubMed ID: 9354446
    [Abstract] [Full Text] [Related]

  • 4. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
    Karle P, Renner M, Salmons B, Günzburg WH.
    Cancer Gene Ther; 2001 Mar 01; 8(3):220-30. PubMed ID: 11332993
    [Abstract] [Full Text] [Related]

  • 5. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
    Günther M, Waxman DJ, Wagner E, Ogris M.
    Cancer Gene Ther; 2006 Aug 01; 13(8):771-9. PubMed ID: 16543915
    [Abstract] [Full Text] [Related]

  • 6. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
    Chen L, Waxman DJ.
    Cancer Res; 1995 Feb 01; 55(3):581-9. PubMed ID: 7834628
    [Abstract] [Full Text] [Related]

  • 7. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P, Waxman DJ.
    Toxicol In Vitro; 2006 Mar 01; 20(2):176-86. PubMed ID: 16293390
    [Abstract] [Full Text] [Related]

  • 8. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
    Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA.
    Clin Cancer Res; 1995 Oct 01; 1(10):1171-7. PubMed ID: 9815909
    [Abstract] [Full Text] [Related]

  • 9. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
    Chen CS, Jounaidi Y, Waxman DJ.
    Drug Metab Dispos; 2005 Sep 01; 33(9):1261-7. PubMed ID: 15919850
    [Abstract] [Full Text] [Related]

  • 10. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450.
    Löhr M, Müller P, Karle P, Stange J, Mitzner S, Jesnowski R, Nizze H, Nebe B, Liebe S, Salmons B, Günzburg WH.
    Gene Ther; 1998 Aug 01; 5(8):1070-8. PubMed ID: 10326030
    [Abstract] [Full Text] [Related]

  • 11. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide.
    Samel S, Keese M, Lux A, Jesnowski R, Prosst R, Saller R, Hafner M, Sturm J, Post S, Löhr M.
    Cancer Gene Ther; 2006 Jan 01; 13(1):65-73. PubMed ID: 16096652
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
    Huang Z, Raychowdhury MK, Waxman DJ.
    Cancer Gene Ther; 2000 Jul 01; 7(7):1034-42. PubMed ID: 10917206
    [Abstract] [Full Text] [Related]

  • 14. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S.
    Anticancer Drug Des; 1999 Dec 01; 14(6):473-86. PubMed ID: 10834269
    [Abstract] [Full Text] [Related]

  • 15. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
    Schwartz PS, Chen CS, Waxman DJ.
    Cancer Gene Ther; 2003 Aug 01; 10(8):571-82. PubMed ID: 12872138
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.